Information Letter on NULOJIX® (belatacept): Increased occurrence of acute graft rejection
2013.03.26
Active substance: belatacept
The pharmaceutical manufacturer is sending out information on the increased occurrence of acute graft rejection under treatment with NULOJIX® (belatacept) associated with rapid corticosteroid taper in patients at high immunologic risk for acute rejection reactions.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN